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osting by EAbstract Type 2 diabetes mellitus is one of the common metabolic disorders that ultimately afﬂicts
large number of individuals. Adrenomedullin (AM) is a potent vasodilator peptide; previous studies
reported development of insulin resistance in aged AM deﬁcient mice. In this study, we employed a
gene delivery approach to explore its potential role in insulin resistance. Four groups were included:
control, diabetic, non-diabetic injected with the AM gene and diabetic injected with the AM gene.
One week following gene delivery, serum glucose, insulin, triglycerides, leptin, adiponectin and cor-
ticosterone were measured as well as the insulin resistance index (HOMA-IR). Soleus muscle glu-
cose uptake and RT-PCR of both AM and glucose transporter-4 (GLUT 4) gene expressions
were assessed. A single tail vein injection of adrenomedullin gene in type 2 diabetic rats improved
skeletal muscle insulin responsiveness with signiﬁcant improvement of soleus muscle glucose
uptake, HOMA-IR, serum glucose, insulin and triglycerides and signiﬁcant increase in muscle
GLUT 4 gene expression (P< 0.05) compared with the non-injected diabetic rats. The beneﬁcial
effects of AM gene delivery were accompanied by a signiﬁcant increase in the serum level of
adiponectin (2.95 ± 0.09 versus 2.33 ± 0.17 lg/ml in the non-injected diabetic group) as well as
a signiﬁcant decrease in leptin and corticosterone levels (7.51 ± 0.51 and 262.88 ± 10.34 versus
10.63 ± 1.4 and 275.86 ± 11.19 ng/ml respectively in the non-injected diabetic group). The1087 89; fax: +20 2 24560282.
(S.M. Younan).
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58 H.Y. Henein et al.conclusion of the study is that AM gene delivery can improve insulin resistance and may have sig-
niﬁcant therapeutic applications in type 2 diabetes mellitus.
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Type 2 diabetes mellitus is a metabolic disease characterized by
relative insulin deﬁciency and associated peripheral insulin
resistance including skeletal muscle, liver, and adipose tissue.
Multiple lines of study have shown that skeletal muscle insulin
resistance is a major determinant of overall insulin resistance
[1]. Improvement in whole body glucose disposal is considered
to be due to the increased insulin-stimulated glucose transport
in skeletal muscle mainly through increased glucose trans-
porter-4 (GLUT 4) protein, the major glucose transporter iso-
form in skeletal muscle [2].
Adrenomedullin (AM) is a potent 52-amino acid vasodila-
tor peptide originally isolated from tissue extracts of human
pheochromocytoma [3]. The gene encoding adrenomedullin
has been mapped and localized to a single locus of chromo-
some 11 and is expressed in a wide range of tissues, such as
in skeletal muscle and adipose tissue [4,5] as well as in adrenal
gland, kidney, heart, lung, spleen, brain, endothelial, and vas-
cular smooth muscle cells [6]. Adrenomedullin is involved in a
variety of biological activities, including vasodilatation, diure-
sis, and inhibition of aldosterone secretion [7].
Xing et al. [8] reported an enhanced development of insulin
resistance by angiotensin II in AM deﬁcient mice. Dobrzynski
et al. [9] investigated the effect of AM gene delivery on the car-
diac and renal function in streptozotocin (STZ)-induced type 2
diabetic rats and reported that it may also affect skeletal mus-
cle, GLUT 4. These ﬁndings may imply potential beneﬁcial ef-
fects of AM gene transfer [10].
To clarify the relationship between AM and insulin resis-
tance, we evaluated muscle glucose uptake and GLUT 4 gene
expression in addition to serum leptin, adiponectin, and corti-
costerone following AM gene delivery in type 2 diabetic rats.Material and methods
Animals and experimental design
Animals were purchased from the animal care unit of Cairo
Medical University; all procedures that involved animals were
approved by this unit. Forty male Wistar albino rats, 12–
14 weeks old, weighing 200–210 g, were each housed in a cage
in a constant temperature (22–24 C) and a light controlled
room on an alternating 12:12 h light–dark cycle and had free
access to food and water.
By the end of the experiment three rats died and the number
was reduced to 37 rats. Animals were divided into the follow-
ing groups:
– Control group (n= 8): rats receiving the standard diet.
– Diabetic group (n= 10): type 2 diabetic rats.
– Non-diabetic-AM group (n= 10): non-diabetic rats injected
with the AM gene.
– Diabetic-AM group (n= 9): diabetic rats injected with the
AM gene.Induction of type 2 diabetes
Beginning on day 0, animals were divided into two groups (20
rats/group): one group was fed a standard rodent diet (SD:
6.5% kcal fat) and the other group was fed a high fat diet
(HFD: 58% kcal fat) for a period of two weeks.
On day 14, rats on the high fat diet (HFD) were injected
intraperitoneally with a single low dose of streptozotocin
(STZ, 45 mg/kg i.p., in 0.01 M citrate buffer pH 4.3, Sigma,
St. Louis, MO, USA) to induce type 2 diabetes mellitus. Both
the low dose of STZ and the high fat diet are essential elements
to induce type 2 diabetes with insulin resistance [11]. Those fed
on standard diet (SD) received only the buffer solution. Subse-
quently all rats had free access to food and water and were
continued on their respective diets till the end of the study.
On day 21, type 2 diabetes was conﬁrmed randomly in some
HFD rats by measuring fasting serum glucose and insulin.
Preparation of adrenomedullin gene
Rat AM gene was ampliﬁed by reverse transcription-polymer-
ase chain reaction (RT-PCR) for 40 cycles and DNA was puri-
ﬁed to prepare cloned DNA (cDNA)/lipid complex using a
DNA puriﬁcation kit. The puriﬁed DNA was then transfected
through dilution of 0.2 lg of DNA with 0.5–5 ll of lipofect-
amine using the lipofectamine transfection kit (invitrogen,
Carlsbad, CA, USA) then injected as 0.2 ml in the rat tail [12].
Animal treatment
On day 21, half the numbers of each of the two groups (dia-
betic and non-diabetic groups) were restrained manually and
0.2 ml of the prepared AM gene was administered via the tail
vein over 10 s using a 3 ml needle [9]. This dose has previously
been shown to result in persistent AM gene expression for up
to ﬁve weeks [13]. The other half was injected only with 0.2 ml
of the lipofectamine vehicle.
Blood and tissue samples
Four weeks after the beginning of the study (one week after the
administration of the adrenomedullin gene), retro-orbital
blood samples (2 ml each) were taken from the rats of all
groups after overnight fasting (9 p.m. to 8 a.m.).
Biochemical and hormonal assays
Fasting serum glucose was measured using the oxidase–
peroxidase method. Serum insulin level was analyzed using
the enzyme-linked immunosorbent assay (ELISA) (Linco
Research) according to the manufacturer’s instructions. Total
cholesterol was determined by the quantitative colorimetric
determination method at 340 nm (EnzyChrom cholesterol
assay kit: ECCH-100). Triglycerides were measured by using
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bance was measured spectrophotometrically at 570 nm.
Serum hormones were assessed by ELISA using the corre-
sponding kits: adiponectin (Linco research, USA), leptin
(Ray Bio research company, USA) and corticosterone (Kami-
ya Biomedical Company, USA).
To estimate insulin resistance, the homeostasis model
assessment for insulin resistance (HOMA-IR: insulin resis-
tance index) was used, calculated as the product of fasting
insulin (in lU/ml) and fasting glucose (in mmol/l) divided by
22.5, which has been used previously in rodents [14].
Muscle collection and preparation
After collection of blood samples, the animals were anesthe-
tized using 65 mg/kg pentobarbital sodium [15], decapitated
and the soleus muscles were dissected. The soleus muscle of
one side was used to assess insulin-dependent glucose uptake
and the other side was used to assess adrenomedullin and glu-
cose transporter-4 (GLUT 4) gene expression.
Competitive RT-PCR method for AM and GLUT 4 mRNAs
Total RNA was extracted from 30 mg of muscle tissue by
using the single-step, acid guanidium thiocyanate, phenol–
chloroform extraction (Promega, Madison, WI, USA) as de-
scribed [16]. The total RNA concentration in each sample
was determined from absorbance at 260 nm, and the quality
of each RNA preparation was determined by 1% agarose-
formaldehyde gel electrophoresis and ethidium bromide stain-
ing. The extracted RNA was reverse transcribed into cDNA
using RT-PCR kit (Stratagene, USA). Moloney murine leuke-
mia virus (MMLV); reverse transcriptase was used for synthe-
sis of cDNA from RNA.
The reverse transcription-polymerase chain reaction speciﬁc
for AM and GLUT 4 was performed as previously described
[13,17]; competitive PCR reactions for each cDNA were per-
formed by preparing a ‘master mix’ containing everything nec-
essary but the primers and competitors. This master mix was
allocated to the tubes containing the respective primers andGlucose uptake ¼ ðGlucose conc: of control sample sample glucose conc: after 1 hÞ  3 ðmedium volumeÞð100 weight of muscle in gÞ :then further subdivided into PCR tubes containing the respec-
tive ‘competitor mix’. Each PCR tube contained a ﬁnal volume
of 25 ll, consisting of 0.1 ll cDNA, 20 mM Tris–HCl (pH 8.4),
50 mM KCl, 2 mM MgCl2, 200 lM dNTP (200 lM each), 5 ll
competitor mix, and 1.25 U platinium thermus aquaticus (Taq)
polymerase (Life Technologies). The competitor mix consisted
of equal amounts of a speciﬁc number of the cut competitor
plasmids diluted in TE solution (10 mM Tris–HCl, 1 mM
EDTA, pH 8) containing 1 ng/ml Salmon Sperm DNA (Sig-
ma, St. Louis, MO, USA). The PCR reactions were performed
in a PTC-200 PCR machine (MJ Research, Watertown, MA,
USA) as follows: denaturation was performed at 95 C,
annealing at 55 C for 1 min, and extension was performed
at 72 C for 2 min, with an additional 10-min incubation at
72 C after completion of the last cycle.After the PCR, the three PCR products were separated on a
2% agarose gel (BioDO, Analyser, Biometra, Germany) and
stained with ethidium bromide. The gel was then photo-
graphed under ultraviolet transillumination.
The quantitative assessment of the PCR products was per-
formed with a computerized video analysis system (Image-1/
FL, Universal Imaging Corp., West Chester, PA).
A fragment of human AM was ampliﬁed by use of AM-
speciﬁc oligonucleotides (forward) 50-TTCGAGTCAAACGC-
TACCGC-30 and 50-ATCAGGCGCTCTCCACC-30 (reverse).
Glut 4 forward primer was GACATTTGGCGGAGCCTAAC
and the reverse was TAACTCCAGCAGGGTGACACAG.
mRNA levels were normalized by the b-actin values in the
samples. The b-actin template was made from two primers:
b-actin sense 5-TGTTGTCCCTGTATGCCTCT-3 and anti-
sense 5-TAATGTCACGCACGATTTCC-3.
Glucose uptake measurement
After isolation, muscles were incubated in Krebs–Henseleit
solution and gassed with carbogen (5% CO2 and 95% O2) as
previously described [18].
The total volume of the buffer was 100 ml; 100 mg glucose
was then added to this volume; insulin (soluble porcine) was
added at a concentration of 250 lU per 1 ml buffer.
The pH of the freshly prepared incubation medium was ad-
justed at 7.4 using pH meter. Then the muscle was transferred
into a sample ﬂask with 3 ml of the incubation medium. In
each set of experiments, one ﬂask containing only 3 ml of incu-
bation medium with no added tissues was used as control. The
ﬂasks were then placed in the metabolic shaker, under a tent of
carbogen gas for 1 h at 37 C with a shaking rate of 100 cycles/
min; the continuous shaking alters the layers of incubation
medium in contact with the gas phase and the muscle. After
incubation, the muscle was immediately dried on ﬁlter paper
and then weighed.
The glucose level was determined in 1 ml of each sample as
well as in 1 ml of the control.
The insulin-stimulated glucose uptake by the muscle was
calculated in mg/g of tissue/h of incubation.Statistical methods
The results were analyzed using the SPSS computer software
package version 10.0 (Chicago, IL, USA). Data were presented
as mean ± SD. Data were evaluated by one-way ANOVA fol-
lowed by post hoc Kruskal–Wallis and Mann–Whitney tests.
Differences of P< 0.05 were considered signiﬁcant.
Results
Effect of AM gene delivery on body weight, serum glucose,
serum insulin and HOMA-IR
As revealed in Table 1, at the end of the experiment the dia-
betic group had signiﬁcantly increased body weight, plasma
Table 1 Metabolic parameters in the studied groups at the end of the study.
Measured parameters Control group Diabetic group Non-diabetic-AM group Diabetic-AM group
Body weight (g) 200.63 ± 9.42 257 ± 9.2* 217 ± 10.05* 252.67 ± 16.853
Serum glucose (mmol/l) 3.88 ± 0.9 10.31 ± 2.2* 3.28 ± 0.77 8.45 ± 1.12+,#
Serum insulin (lU/ml) 10.89 ± 1.08 31.92 ± 6.8* 12.09 ± 0.85 22.43 ± 4.32+,#
HOMA-IR 1.84 ± 0.3 15 ± 5.73* 1.76 ± 0.43 8.45 ± 2.08+,#
* Signiﬁcantly compared to control group.
+ Signiﬁcantly compared to diabetic group.
# Signiﬁcantly compared to non-diabetic-AM group.
60 H.Y. Henein et al.glucose and insulin levels as well as the HOMA-IR compared
to the control group (P< 0.05). The non-diabetic-AM group
showed a signiﬁcant increase in the body weight (P< 0.05)
compared to the control group but without signiﬁcant differ-
ences in serum glucose and insulin levels as well as in the
HOMA-IR (P> 0.05).
The diabetic-AM group had a highly signiﬁcantly increased
body weight, serum glucose and insulin and HOMA-IR com-
pared to the non-diabetic-AM group (P< 0.001). Compared
to the diabetic group, the diabetic-AM group showed no statis-
tical signiﬁcance in body weight (P> 0.05), while serum glu-
cose and insulin and HOMA-IR were signiﬁcantly improved
(P< 0.001), denoting the beneﬁcial effect of AM gene delivery
on insulin resistance.
Effect of AM gene delivery on serum triglycerides and
cholesterol
As shown in Table 2, the diabetic group had a highly signiﬁ-
cantly elevated serum cholesterol (P< 0.001) without a signif-
icant increase in its serum triglycerides compared to the
control group. There were no signiﬁcant differences in both
serum TG and cholesterol between the non-diabetic-AM and
the control group (P> 0.05), and the diabetic-AM group still
had a signiﬁcantly elevated serum level of cholesterol com-
pared to the non-diabetic-AM group (P< 0.05).Table 2 Serum triglycerides and cholesterol in the studied groups a
Measured parameters Control group Diabetic gr
Serum triglycerides (mg/dl) 63.68 ± 4.87 70.2 ± 7
Serum cholesterol (mg/dl) 129.5 ± 8.53 159.47 ± 1
* Signiﬁcantly compared to control group.
+ Signiﬁcantly compared to diabetic group.
# Signiﬁcantly compared to non-diabetic-AM group.
Table 3 Serum corticosterone, leptin and adiponectin in the studie
Measured parameters Control group Diabetic g
Serum corticosterone (ng/ml) 250.37 ± 9.28 275.86 ± 1
Serum leptin (ng/ml) 3.49 ± 0.56 10.63 ± 1
Serum adiponectin (lg/ml) 3.76 ± 0.23 2.33 ± 0
* Signiﬁcantly compared to control group.
+ Signiﬁcantly compared to diabetic group.
# Signiﬁcantly compared to non-diabetic-AM group.AM gene delivery improved serum TG and cholesterol of
the diabetic-AM group compared to the diabetic group
(P< 0.05), highlighting another beneﬁcial effect of AM in
type 2 diabetes.
Effect of AM gene delivery on serum corticosterone, leptin and
adiponectin
As observed in Table 3, at the end of the study the diabetic and
the diabetic-AM groups showed a signiﬁcant increase of serum
corticosterone and leptin levels with a signiﬁcant decrease in
serum adiponectin (P< 0.05) compared to the control and
non-diabetic-AM groups respectively. No statistical signiﬁ-
cance was demonstrated in these parameters between the
non-diabetic-AM group and the control group; the diabetic-
AM group showed a signiﬁcant decrease in serum corticoste-
rone and leptin and a signiﬁcant increase in serum adiponectin
(P< 0.05) compared to the diabetic group, which may con-
tribute to the improvement of the insulin resistance state fol-
lowing AM gene delivery.
Effect of AM gene delivery on muscle glucose uptake and GLUT
4 expression
Fig. 1A and B reveal that the diabetic group muscle adreno-
medullin expression compared to the control group was nott the end of the study.
oup Non-diabetic-AM group Diabetic-AM group
.2 58.6 ± 6.35 61.58 ± 4.07+
6.9* 126.83 ± 5.01 144.8 ± 9.75+,#
d groups at the end of the study.
roup Non-diabetic-AM group Diabetic-AM group
1.19* 240.05 ± 7.52 262.88 ± 10.34+,#
.4* 4.22 ± 0.5 7.51 ± 0.57+,#
.17* 3.91 ± 0.22 2.95 ± 0.09+,#
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Fig. 1 Soleus muscle adrenomedullin in the different groups. PCR products of adrenomedullin mRNA compared to b-actin (A) and
adrenomedullin muscle level in arbitary units (B) in the different studied groups. *Signiﬁcantly compared to control group. +Signiﬁcantly
compared to diabetic group.
0
1
2
3
4
5
Control Diabetic non-diabetic-AM Diabetic-AM
+
M
us
cl
e 
glu
co
se
 u
pt
ak
e 
*
*
(m
g/
g 
tis
su
e
/h
ou
r)
Fig. 2 Soleus muscle glucose uptake in the different studied
groups. *Signiﬁcant compared to control group. +Signiﬁcantly
compared to diabetic group.
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uptake (Fig. 2) and GLUT 4 expression (Fig. 3A and B) were
signiﬁcantly decreased (P< 0.05).
The diabetic-AM group showed no statistically signiﬁcant
difference in either muscle adrenomedullin expression or glu-
cose uptake (Figs. 1 and 2) (P> 0.05), while it still showed
a signiﬁcant decrease in GLUT 4 expression compared to the
non-diabetic-AM group (P< 0.001) (Fig. 3).
Meanwhile AM gene delivery signiﬁcantly increased muscle
adrenomedullin expression, glucose uptake and GLUT 4
expression (P< 0.01) in the non-diabetic-AM and diabetic-
AM groups compared to the control and the diabetic groups
respectively.
Discussion
Insulin resistance has received great attention because of its
public health importance. Many studies have tried and con-
tinue to try to improve it. In this study, AM gene delivery in
non-diabetic-AM and in diabetic-AM rats was capable ofimproving soleus muscle insulin-stimulated glucose uptake
and GLUT 4 expression compared to their controls not receiv-
ing AM gene delivery. In addition it improved the measures of
insulin resistance (plasma glucose, insulin and cholesterol as
well as HOMA-IR) in the diabetic group. These ﬁndings indi-
cate a promising effect of AM gene delivery in insulin
resistance.
Similarly, Dobrzynski et al. [9] observed an increased skel-
etal muscle membrane-bound GLUT 4, which has improved
glucose utilization of AM-treated STZ-diabetic rats. They
attributed this effect to AM interaction via the Akt pathway.
Furthermore, insulin-stimulated glucose uptake into the iso-
lated skeletal muscle was signiﬁcantly attenuated in aged
AM deﬁcient (AM+/) mice [19].
In the L6 skeletal muscle cell line, adrenomedullin can bind
to CGRP receptors, activating adenylate cyclase and cAMP-
dependent protein kinases [20]. Nishimatsu et al. [21] reported
that AM is capable of directly activating Akt via phosphatidyl-
inositol 3-kinase (PI-3 kinase) in rat aorta. Phosphorylated
Akt can also stimulate cellular glucose usage and stimulate
GLUT 4 translocation to the membrane in skeletal muscle
[22]. These known Akt activities could help explain the ob-
served beneﬁcial effects of AM gene delivery in the STZ-in-
duced diabetic rats in this study.
Previous studies indicated that skeletal muscle-speciﬁc inhi-
bition of insulin signaling is adequate to cause insulin resis-
tance [23]. Insulin increases skeletal muscle glucose transport
through translocation of the GLUT 4 isoform of the glucose
transporter from intracellular sites to the cell surface [24].
There is a good correlation between the GLUT 4 content of
a muscle and maximally stimulated glucose uptake [25].
In contrast, Garvey et al. [26] found that the muscle GLUT
4 glucose transporter level was normal in type 2 diabetes,
and stated that the insulin resistance is due to impaired
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Fig. 3 Soleus muscle GLUT 4 the different groups. PCR products of GLUT 4 mRNA (A) and its muscle level in different groups in
arbitary units (B). *Signiﬁcantly compared to control group. +Signiﬁcantly compared to diabetic group. #Signiﬁcantly compared to non-
diabetic-AM group.
62 H.Y. Henein et al.translocation and trafﬁcking of intracellular GLUT 4 with
consequent accumulation of GLUT 4 in a dense membrane
compartment from which insulin is unable to recruit GLUT
4 to the cell surface.
Multiple lines of study have shown diabetic patients to have
increased oxidative stress. Moreover, in vitro study has demon-
strated reactive oxygen species (ROS) to impair insulin inter-
nalization in endothelial cells [27], block insulin receptor
substrate (IRS) phosphorylation, and impair PI-3 kinase activ-
ity in hepatocytes [28], and reduce the translocation of GLUT
4 in adipocytes [29].
The AM-ROS axis may play a role in the pathophysiology
of insulin resistance. AM has been shown to be up-regulated
by ROS [30]. It was also reported that a deﬁciency of AM in-
duces a higher oxidative stress by stimulating ROS production,
but not by impairing the scavenging system that is regulated by
AM and that AM not only inhibited ROS production but also
had better effect on glucose homeostasis compared to superox-
ide dismutase mimetic [31]. Since it has been suggested that the
production of activated oxygen species has a major role in the
development of STZ-induced diabetes [32], the antioxidant ef-
fect of AM could be another plausible mechanism by which
AM could improve insulin resistance, although ROS were
not measured in this work.
In the current study, serum leptin and corticosterone were
signiﬁcantly increased in the STZ-diabetic group compared
to the control group while serum adiponectin was signiﬁcantly
decreased. Previous studies reported that diabetes is associated
with elevated plasma levels of glucocorticoids. Contributors
include: a hyperactive hypothalamic–pituitary–adrenal axis
with increasing signaling by hypothalamic CRH and increased
adrenal glucocorticoid production [33] and abnormalities in
negative feedback regulation by cortisol at the pituitary level
due to some metabolic disorders [34]. Increased body weight,
glucocorticoids and insulin as well as the high fat diet increase
leptin secretion [35] and can explain our ﬁnding in the diabetic
group. Moreover, the reduction of serum adiponectin, the
most abundant adipose-secreted protein, may be related toatrophy of adipocytes and/or other diseases that might be in-
duced by diabetes mellitus [36].
Iemura Inaba et al. [37] suggested that AM may improve
glucose intolerance via improving glucose incorporation in
adipose tissue. Fukai et al. [5] demonstrated AM expression
in adipocytes of obese rats and speculated that the upregula-
tion of AM may contribute to adipokine dysregulation and
development of metabolic syndrome; however, these authors
did not investigate such a hypothesis.
Interestingly, AM gene delivery in the current study was
accompanied by a signiﬁcant increase in the serum adiponectin
level and a decrease in both corticosterone and leptin levels in
the diabetic-AM group compared with the non-injected dia-
betic group, with concomitant improvement in the insulin
resistance state.
It is well known that glucocorticoid excess contributes to
muscle insulin resistance and reduces glucose uptake by
decreasing GLUT 4 translocation to the cell surface [38] and
adiponectin can decrease insulin resistance by enhancing fatty
acid oxidation and glucose disposal in muscle and liver
through the AMP kinase [39]. In addition, adiponectin poten-
tiates the effects of leptin on glucose and lipid oxidation [40]
and has an anti-inﬂammatory effect [41]. Thus reduction of
corticosterone and increase in adiponectin can contribute to
amelioration of the insulin resistance state seen in the dia-
betic-AM group.
The effects of AM on adrenal glucocorticoid release are
doubtful and probably mediated by the increase in adrenal
blood ﬂow rate and the inhibition of ACTH release by pitui-
tary corticotropes [14]. The decrease in both serum insulin
and corticosterone in the diabetic-AM group can explain the
decrease in leptin level. Also to our knowledge AM has no di-
rect stimulatory effect on adiponectin secretion but may have
an indirect effect through decreasing corticosterone, which is
known to inhibit adiponectin secretion [42]. Moreover, adipo-
nectin levels increase when insulin sensitivity improves [43].
In the present study, the type 2 diabetic group showed a
non-signiﬁcant difference in soleus muscle adrenomedullin
Effect of adrenomedullin gene delivery on insulin resistance 63gene expression although it showed other parameters of insulin
resistance together with reduced insulin stimulated muscle glu-
cose uptake and muscle GLUT 4 content compared to the con-
trol group.
The role of hyperglycemia in upregulating adrenomedullin
is controversial. In vitro data suggested that hyperglycemia
might increase vascular adrenomedullin expression [44]. How-
ever, this notion could not be substantiated in vivo [45], and
other studies found an increase in circulating AM in patients
with type 2 diabetes and attributed this to acute hyperinsuline-
mia [46] and increased oxidative stress [47].
In this study the AM gene was delivered to diabetic rats.
However, many physiological conditions such as exercise
[48], moving from low to high altitude [49] and pregnancy in
both rats [50] and women [51] can increase plasma adrenomed-
ullin. However, it is difﬁcult to describe the exact mechanisms
that regulate adrenomedullin synthesis and secretion in vivo.
With respect to the effect of adrenomedullin on insulin
secretion, conﬂicting results have been found. Speciﬁcally,
Mulder et al. [52] ﬁrst reported the stimulatory effects of adre-
nomedullin on insulin secretion from isolated rat islets, while
Martinez et al. [53] clearly demonstrated the inhibitory role
of adrenomedullin on insulin secretion in vitro that might play
a role in the homeostasis of pancreatic islets. The vasodilatory
effect of adrenomedullin may also have some inﬂuence on
insulin secretion by elevating the pancreatic perfusion rate,
but this remains to be proven. In this study serum insulin in
the diabetic group receiving AM was signiﬁcantly decreased
but it still remains to be proven whether this is attributable
to improved insulin resistance or to a direct effect of AM on
the pancreas.
Conclusions
In this study, we demonstrated that AM may be a potentially
useful peptide to counteract the deleterious effects of a diabetic
state through its upregulating effect on skeletal muscle GLUT
4, reduction in serum corticosterone and improvement of ser-
um adiponectin and this may stimulate future investigation
into the potential therapeutic use of AM in insulin resistance.References
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